Finoriq research workspace
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Institutional Holdings & 13F Ownership
Charles River Laboratories International, Inc. provides drug discovery, non-clinical. Review CRL institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Company
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
- Ticker
- CRL
- Market Cap
- $10.7B
- Latest Price
- $221.11
- Industry
- Biotech & Pharma
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Top Institutional Holders
Top current 13F holders indexed for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Bill Nygren (advisor level)CIK 0000813917 | $371.4M | 0.5% | Filing2026-05-15 |
| 2 | John RogersCIK 0000936753 | $249.1M | 2.8% | Filing2026-05-14 |
| 3 | Joel GreenblattCIK 0001510387 | $61.8M | 0.19% | Filing2026-05-15 |
| 4 | Lee AinslieCIK 0000934639 | $1.4M | 0.02% | Filing2026-05-15 |
| 5 | Ray DalioCIK 0001350694 | $1.2M | 0.01% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.